Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune condition in which the body's own defenses turn against the optic nerves and spinal cord. This confusion leads to inflammation that can rob people of their ...
Anti-T-lymphocyte globulin (ATLG) for the prevention of graft-versus-host disease (GvHD) reduces complications and infection-related mortality compared with post-transplant cyclophosphamide (PTCy) in allogeneic hematopoietic ...
Jun 15, 2026
0
2
With the publication of the long-term data from the RELAZA2 study, a research program developed over many years by Dresden University Medicine for the treatment of leukemia patients, has reached an important milestone. The ...
May 31, 2026
0
8
Having a preexisting autoimmune disease is an independent risk factor for poor outcomes with myelodysplastic syndrome (MDS), according to a study published in the June issue of Clinical Immunology.
May 29, 2026
0
4
A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel combination therapy that significantly improves treatment ...
May 21, 2026
0
6
A key molecular dynamic could be the key to fighting tumors while allowing patients to still receive life-saving cell transplantation, according to the latest finding published by a team of scientists from the Hackensack ...
Apr 28, 2026
0
6
Results of a Phase I clinical trial show that patients who undergo a blood stem cell transplant involving a donor have a lower risk of relapse and lower rates of graft-versus-host disease when they receive the targeted therapy ...
Mar 29, 2026
0
5
Cancer researchers are making strides in efforts to use genetic profiling to develop a more precise understanding of the response to treatment of acute myeloid leukemia (AML), a rare but aggressive blood cancer.
Feb 19, 2026
0
12
The American Society of Hematology (ASH) released guidelines on frontline management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), as well as the management of relapsed or refractory disease ...
Feb 11, 2026
0
5
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received chemotherapy-based conditioning ...
Dec 8, 2025
0
5
